Evidence map›Paper›PMID 37996453›Full record

ArticleScientific reports2023

The DRESDEN PLATFORM is a research hub for ultra-high dose rate radiobiology.

Josefine Metzkes-Ng, Florian-Emanuel Brack, Florian Kroll, Constantin Bernert, Stefan Bock, Elisabeth Bodenstein, Michael Brand, Thomas E Cowan, René Gebhardt, Stefan Hans and 21 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 8 institutions in 3 countries.

Josefine Metzkes-Ng *Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Florian-Emanuel Brack *Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Florian Kroll *Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Constantin BernertHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Stefan BockHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Elisabeth BodensteinHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Michael BrandCenter for Regenerative Therapies (CRTD), TUD Dresden University of Technology, Dresden, Germany.
Thomas E CowanHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
René GebhardtHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Stefan HansCenter for Regenerative Therapies (CRTD), TUD Dresden University of Technology, Dresden, Germany.
Uwe HelbigHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Felix HorstHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Jeannette JansenGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Stephan D KraftHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Mechthild KrauseHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Elisabeth LeßmannHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Steffen LöckOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Jörg PawelkeHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Thomas PüschelHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Marvin ReimoldHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Martin RehwaldHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Christian RichterHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Hans-Peter SchlenvoigtHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Ulrich SchrammHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Michael SchürerOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Joao SecoGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Emília Rita SzabóELI ALPS, ELI-HU Non-Profit Ltd., Szeged, Hungary.
Marvin E P UmlandtHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Karl ZeilHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Tim ZieglerHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Elke BeyreutherHelmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. e.beyreuther@hzdr.de.
Helmholtz-Zentrum Dresden-Rossendorf · DETU Dresden · DEELI-HU Research and Development Non-Profit · HUGerman Cancer Research Center · DEHeidelberg University · DENational Center for Tumor Diseases · DEOncoRay · DEUniversity Hospital Carl Gustav Carus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recently observed FLASH effect describes the observation of normal tissue protection by ultra-high dose rates (UHDR), or dose delivery in a fraction of a second, at similar tumor-killing efficacy of conventional dose delivery and promises great benefits for radiotherapy patients. Dedicated studies are now necessary to define a robust set of dose application parameters for FLASH radiotherapy and to identify underlying mechanisms. These studies require particle accelerators with variable temporal dose application characteristics for numerous radiation qualities, equipped for preclinical radiobiological research. Here we present the DRESDEN PLATFORM, a research hub for ultra-high dose rate radiobiology. By uniting clinical and research accelerators with radiobiology infrastructure and know-how, the DRESDEN PLATFORM offers a unique environment for studying the FLASH effect. We introduce its experimental capabilities and demonstrate the platform's suitability for systematic investigation of FLASH by presenting results from a concerted in vivo radiobiology study with zebrafish embryos. The comparative pre-clinical study was conducted across one electron and two proton accelerator facilities, including an advanced laser-driven proton source applied for FLASH-relevant in vivo irradiations for the first time. The data show a protective effect of UHDR irradiation up to [Formula: see text] and suggests consistency of the protective effect even at escalated dose rates of [Formula: see text]. With the first clinical FLASH studies underway, research facilities like the DRESDEN PLATFORM, addressing the open questions surrounding FLASH, are essential to accelerate FLASH's translation into clinical practice.

Indexed as

NeoplasmsProtonsAnimalsHumansRadiobiologyRadiotherapy DosageZebrafishProtons

Identifiers

PMID37996453
PMCPMC10667545
OpenAlexW4388939005

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.